{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:38Z","timestamp":1790255198714,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["KK2631-20"],"award-info":[{"award-number":["KK2631-20"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["BSF25-304"],"award-info":[{"award-number":["BSF25-304"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2025-02223194"],"award-info":[{"award-number":["RS-2025-02223194"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-24536373"],"award-info":[{"award-number":["RS-2025-24536373"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201280","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:31:10Z","timestamp":1782315070000},"page":"201280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reversible control of CAR T cells through PROTAC compound targeting bromodomain mutant"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6637-8571","authenticated-orcid":false,"given":"Yeongrin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji U.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonjung","family":"Jeun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung Kyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Un","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5471-0903","authenticated-orcid":false,"given":"Chi Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201280_bib1","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201280_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201280_bib3","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201280_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201280_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201280_bib6","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201280_bib7","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201280_bib8","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201280_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564099","article-title":"Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201280_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41587-019-0403-9","article-title":"A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy","volume":"38","author":"Giordano-Attianese","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201280_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201280_bib12","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1016\/j.ymthe.2025.01.012","article-title":"The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy","volume":"33","author":"Zhong","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201280_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201280_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acssynbio.9b00476","article-title":"A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology","volume":"9","author":"Lee","year":"2020","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.omton.2026.201280_bib15","doi-asserted-by":"crossref","first-page":"15477","DOI":"10.1021\/acs.jmedchem.1c01532","article-title":"Development of BromoTag: A \u201cBump-and-Hole\u201d-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins","volume":"64","author":"Bond","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201280_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201280_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201280_bib18","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.immuni.2024.04.025","article-title":"A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death","volume":"57","author":"Mannion","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201280_bib19","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201280_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.672267","article-title":"From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation","volume":"9","author":"Cecchini","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.omton.2026.201280_bib21","first-page":"802","article-title":"CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"14","author":"Davila","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201280_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201280_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201280_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094320","article-title":"Pharmacologic Control of CAR T Cells","volume":"22","author":"Caulier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201280_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228620","article-title":"Engineering Next-Generation CAR-T Cells for Better Toxicity Management","volume":"21","author":"Andrea","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201280_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.691093","article-title":"Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy","volume":"9","author":"Yuan","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.omton.2026.201280_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201280_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201280_bib29","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1016\/j.ymthe.2023.10.020","article-title":"A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy","volume":"31","author":"Lee","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201280_bib30","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bbrc.2018.06.091","article-title":"A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening","volume":"503","author":"Kim","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:33:37Z","timestamp":1790253217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001566"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201280","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversible control of CAR T cells through PROTAC compound targeting bromodomain mutant","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201280"}}